Literature DB >> 12699135

Evaluation of the effect of the sublingually administered nifedipine and captopril via transcranial doppler ultrasonography during hypertensive crisis.

Kani Gemici1, Ibrahim Baran, Mustafa Bakar, Celalettin Demircan, Bülent Ozdemir, Jale Cordan.   

Abstract

OBJECTIVE: This study was designed to show the effects of sublingually administered nifedipine and captopril on middle cerebral arterial blood flow during hypertensive crisis in the emergency department. METHODS AND
RESULTS: Transcranial Doppler ultrasonography (TCD) was performed on the patients fulfilling the criteria (15 patients given captopril, 13 patients given nifedipine, mean (+/-SD) age 56 +/- 11 and 54 +/- 10 years, respectively). Then, patients were randomized into sublingually administered captopril or nifedipine groups and after the drug administration, TCD was repeated. Initial systolic and diastolic blood pressures were 200 +/- 21/125 +/- 21 mmHg in the captopril group and 199 +/- 17/ 123 +/- 20 mmHg in the nifedipine group. There was no significant difference between antihypertensive effects of the drugs after initiation of treatment. Before the treatment with captopril, middle cerebral artery (MCA) flow velocities (Vm) and pulsatility index (PI) were 76.74 +/- 6.38 cm/s and 1.18 +/- 0.09, respectively. The values after the treatment with captopril were 78.21 +/- 5.24cm/s (p < 0.05) and 0.92 +/- 0.08 (p < 0.001), respectively. Before the treatment with nifedipine, Vm and PIs were 64.73 +/- 5.11 cm/s and 1.14 +/- 0.18, respectively. After the treatment with nifedipine, Vm was 60.04 +/- 5.36 cm/s (p < 0.01) and PI was 1.21 +/- 0.09 (p < 0.01).
CONCLUSION: After treatment with captopril, PIs were decreased to normal limits but in the group treated with nifedipine, PIs increased to more pathological values. These results showed that we should reconsider the use of nifedipine in the emergency departments as an antihypertensive agent in hypertensive attack treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699135

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  6 in total

1.  The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.

Authors:  Hein A van Onzenoort; Michiel Bussink; Paul P Menheere; Walther N van Mook; Paul-Hugo M van der Kuy
Journal:  Pharm World Sci       Date:  2006-09-27

2.  Differences in Diagnosis and Management of Hypertensive Urgencies and Emergencies According to Italian Doctors from Different Departments Who Deal With Acute Increase in Blood Pressure-Data from Gear (Gestione Dell'emergenza e Urgenza in ARea Critica) Study.

Authors:  Francesca Saladini; Costantino Mancusi; Fabio Bertacchini; Francesco Spannella; Alessandro Maloberti; Alessandra Giavarini; Martina Rosticci; Rosa Maria Bruno; Giacomo Pucci; Davide Grassi; Martino Pengo; Maria Lorenza Muiesan
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

3.  Cerebral oxygenation and haemodynamic effects induced by nimodipine in healthy subjects.

Authors:  Daniela Canova; Silvestro Roatta; Giuseppe Micieli; Daniele Bosone
Journal:  Funct Neurol       Date:  2012 Jul-Sep

Review 4.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

Review 5.  Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation.

Authors:  Jurgen A H R Claassen; Dick H J Thijssen; Ronney B Panerai; Frank M Faraci
Journal:  Physiol Rev       Date:  2021-03-26       Impact factor: 37.312

6.  Pharmacologic Treatment of Hypertensive Urgency in the Outpatient Setting: A Systematic Review.

Authors:  Claudia L Campos; Charles T Herring; Asima N Ali; Deanna N Jones; James L Wofford; Augustus L Caine; Robert L Bloomfield; Janine Tillett; Karen S Oles
Journal:  J Gen Intern Med       Date:  2018-01-16       Impact factor: 5.128

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.